Licensing/Collaborating with NIH to Bring New Products to Market

Do you want to bring the next life-changing health innovation to market? NIH is a premier technology transfer partner with over 1500 technologies available for licensing or collaboration. Partnerships using NIH technologies are behind highly impactful products including HPV vaccines, mRNA COVID-19 vaccines, and more. Check out the expansive collection of leading edge technologies from award winning NIH inventors available for licensing or collaboration on our website.

Why license from or collaborate with the NIH?

Reasonable and Flexible terms

  • 0% equity and 0-15% overhead rate
  • Won't take your IP
  • Do not need partner funds to support operations

Prestige Factor

  • Collaboration: higher company profile
  • World-renowned researchers and resources
  • Assets historically more likely to be first-in-class or exhibit a novel mechanism of action

History of Success

  • Significant clinical and translational resources to support technology development
  • Significant record of success: 47 FDA-approved drugs and vaccines based on NIH patents

Explore NIH Technologies

Explore work by over 1,500 NIH researchers   |   Available for Licensing & Collaboration


Our partners include:

  • Pharma and biotech companies interested in solving a specific technical issue, tapping into world-class resources, or expanding their business through licensing technology from NIH 
  • Investors (angels, venture capital, private equity, etc.) starting a new company or adding to the pipeline of portfolio companies 
  • Academics interested in finding a collaborator or research materials 
  • Nonprofits interested in finding treatment options for patients or developing NIH technologies 

Success Stories


Comirnaty® product photoComirnaty®, colloquially known as the Pfizer vaccine, is a messenger RNA (mRNA) vaccine indicated for active immunization to prevent COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This vaccine by BioNTech/Pfizer received full FDA approval on August 23, 2021, after entering the market in 2020 on an Emergency Use Authorization.

Comirnaty was developed from technology licensed from the NIH. National Institute of Allergy and Infectious Diseases (NIAID) inventors and their collaborators had already developed a stabilized prefusion coronavirus spike protein that could be used as a vaccine antigen to cause neutralizing antibody responses. 

Once the SARS-CoV-2 genome sequence was released members of the same collaborative team worked to generate an engineered version of the SARS-CoV-2 spike protein and the mRNA to generate it upon delivery. 

This allows the body to create an immune response so that the body can see a novel coronavirus before a person gets infected and therefore prevent that infection.


Spravato® product photoSpravato ® is the first FDA approved prescription nasal spray for adults who suffer from treatment-resistant depression (TRD). Spravato was developed by Janssen Therapeutics from technology developed from a collaboration between the National Institute of Mental Health (NIMH), Yale University and Mount Sinai Health System. This discovery was developed from esketamine, the S-enantiomer of ketamine, as a treatment for adults who have tried other antidepressant medicines but did not benefit from them. Spravato immediately impacts brain cells whereas common antidepressants often take several weeks. Due to Spravato’s fast acting nature, it can be used in acute crisis such as imminent risk of suicide. Spravato is administered in a clinic setting by giving three doses spaced five minutes apart and is to be used in conjunction with an oral antidepressant.

The development of Spravato resulted in the first antidepressant in 60 years that was significantly different from other drugs on the market. Common antidepressants increase levels of serotonin, norepinephrine, and dopamine. Spravato does this as well, but also increases levels of glutamate. Glutamate is the most abundant chemical messenger in the brain and allows the Spravato to have a larger impact on more brain cells at once.

Spravato received FDA approval on March 6, 2019 and was first to market with their antidepressant nasal spray for TRD.

Upcoming Events

2024 National Cancer Institute/Frederick National Lab Technology Showcase

An annual event for potential industry partners and stakeholders highlighting cancer technologies and how to work with the NCI and the Frederick National Laboratory.

September 4, 2024 | 9:00 AM – 4:30 PM
Frederick, MD


Technology Opportunity Webinars

The National Cancer Institute regularly hosts webinar’s with inventors to promote specific opportunities. More info on upcoming events can be found on the NCI TTC website.  

Featured Opportunities

Coming soon...